What is “antihemophilic factor (recombinant pegylated)”?
“Antihemophilic factor recombinant pegylated” refers to a recombinant clotting factor VIII product (factor replacement therapy) that has been chemically modified (pegylated) to extend its activity in the body. These drugs are used to prevent and control bleeding in people with hemophilia A (congenital factor VIII deficiency).
Which pegylated recombinant factor VIII products exist?
Common pegylated recombinant factor VIII brands have included:
- Adynovate (not pegylated; it’s a different recombinant factor VIII formulation)
- N8-GP / Jivi (pegylated recombinant factor VIII; used for hemophilia A)
If you’re trying to identify a specific medicine, the exact brand name matters because “recombinant pegylated” is a descriptive label that can match different products.
What conditions is it used for?
Pegylated recombinant antihemophilic factor products are used for:
- Hemophilia A (prophylaxis to prevent bleeds)
- On-demand treatment of bleeding episodes
The exact indications (age limits, dosing schedule, and whether it’s approved for both prophylaxis and treatment) depend on the specific branded drug.
How does pegylation change dosing and bleed protection?
Pegylation slows the clearance of the factor so it can last longer in circulation. That typically supports:
- Less frequent dosing than non-pegylated factor VIII products
- Sustained factor VIII activity to help prevent bleeding events
The clinical effect (how long it lasts and how effective it is) depends on the individual product and regimen.
What are common side effects or risks people ask about?
Across factor VIII replacement therapies, the main risks patients and clinicians focus on include:
- Injection-site reactions
- Headache
- Allergic reactions
- Inhibitor development (the immune system forming antibodies that reduce factor VIII effectiveness)
Inhibitors are the key long-term risk with hemophilia A factor products.
Is it possible to find patent/exclusivity info for pegylated recombinant antihemophilic factor?
If your goal is to identify the specific product and then check who owns the patents/exclusivity (or when generic/biosimilar competition could be expected), DrugPatentWatch can help track filings and status for particular brands. You can search by the exact name once you know the brand. (DrugPatentWatch is a useful reference for patent-related questions.)
Source: https://www.drugpatentwatch.com/
What do I need from you to give a precise answer?
“Antihemophilic factor recombinant pegylated” could refer to multiple label descriptions. Share any of the following and I’ll map it to the exact drug with indications, dosing approach, and the relevant patent/exclusivity references:
- the brand name
- the generic/INN name (if shown on the label)
- a company/manufacturer name
- the label text around “pegylated” or the strength (e.g., IU/vial)
Sources
- DrugPatentWatch